Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azelastine spray versus budesonide spray in allergic rhinitis
IRCT20170806035536N2Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of azelastine and budesonide in allergic rhinitis (AR) (3 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoints: Treatment status of allergic rhinitis and Five clinical signs of allergic rhinitis. Started Aug 2017; status: completed.
02
Drugs
azelastinebudesonide
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on IRCT20170806035536N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170806035536N2.